Skip to main content

Potassium

CPT

84132

Test Details

Methodology

Ion-selective electrode (ISE)

Result Turnaround Time

Within 1 day

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Use

This test is used to evaluate electrolyte balance; follow patients on diuretic therapy and with renal diseases, particularly salt-losing nephropathy; evaluate patients being treated for acidosis; prevent cardiac arrhythmias; evaluate alcoholism with delirium tremens; evaluate and treat ketoacidosis in diabetes mellitus; evaluate acid-base balance, water balance; manage intravenous therapy; evaluate anion gap; evaluate muscular weakness, leukemia, disease of the gastrointestinal tract including laxative abuse, large villous adenomas, emesis, fistulas and tube drainage; detect, diagnose, and manage mineral corticoid excess (primary aldosteronism, Cushing syndrome, tumor with ectopic ACTH production, some cases of congenital adrenal hyperplasia) and licorice ingestion. Potassium is increased in oliguria, anuria, urinary obstruction, renal failure due to shock (decreased removal of potassium) and renal tubular acidosis. Potassium is decreased in three ways:

  • inadequate intake
  • excessive loss due to diarrhea or vomiting or decreased reabsorption due to increased secretion of mineralocorticosteroids
  • movement into the cell as occurs with conditions causing alkalosis

Custom Additional Information

Hypokalemia (low potassium) has been found in >90% of hypertensive patients with primary aldosteronism (Conn syndrome). This uncommon entity is a curable cause of hypertension. Low potassium occurs with endogenous or exogenous increase in other corticosteoids, including that in Cushing syndrome, as well as with dietary or parenteral deprivation of potassium (e.g., parenteral therapy without adequate potassium replacement). Hypokalemia occurs with vomiting, diarrhea, fistulas, laxatives, diuretics, burns, excessive perspiration, Bartter syndrome, some cases of alcoholism and folic acid deficiency, in alkalosis and in renal tubular acidosis, as well as in other entities. Low potassium is much more significant with a low pH than with a high pH. When pH increases by 0.1, potassium decreases approximately 0.6 mmol/L. With low pH, as in ketoacidosis, as therapeutic adjustment towards normal is made, plasma/serum K(+) levels will decrease. Phosphorous levels tend to follow potassium levels downwards during therapy of diabetic ketoacidosis; both are largely intracellular. With insulin therapy (and increased utilization of carbohydrates), potassium moves into cells and serum/plasma level falls. Hyperalimentation may have a similar effect. Hypokalemia has been reported in slightly more than one-half of a series of 32 patients with acute myelogenous leukemia,1 but thrombocytosis can increase serum potassium levels, vide supra. Thiazide/chlorthalidone therapy may cause hyperuricemia and hypercalcemia as well as hypokalemia. The watery diarrhea-hypokalemia-achlorhydria (WDHA) syndrome most often is related to vasoactive intestinal polypeptide (VIP).

Hyperkalemia (high potassium) reflects generally inadequate renal excretion, mobilization of potassium from the tissues or excessive intake or administration. Hyperkalemia occurs with hemolysis, trauma, with administration of potassium salts of some drugs, Addison disease, acidosis, insulin lack, with increased osmolality (e.g., glucose, mannitol), and in other entities as well as with renal diseases. Increased potassium can occur with potassium sparing diuretics, nonsteroidal anti-inflammatory drugs, especially in the presence of other factors. 

A discussion of the relation between lactic acidosis and ketoacidosis and elevated serum potassium levels is provided in a paper by Fulop.2 Drug effects are summarized.3

Pseudo hyperkalemia (PHK), or falsely elevated potassium, occurs due to a wide range of pre-analytical factors, include specimen collection, processing and handling, and certain physiological factors.4,5 Any one or a combination of the following may result in a falsely elevated potassium:

Collection4,5

  • fist clenching—causes local release of potassium during contraction of forearm muscles
  • prolonged tourniquet application—causes hemoconcentration and possible hematoma affecting water balance of cells and cell lysis that can lead to elevated potassium
  • traumatic collection (mechanical factors)—cell lysis due to mechanical factors such as the use of smaller gauge needles (e.g., use of butterfly needle), excessive force with syringe draws and vigorous mixing may increase the risk of cell lysis
  • incorrect order of collection or draw—collection of K+EDTA sample immediately prior to drawing an SST can cause carryover of the additive into serum tubes causing artificially elevated potassium
  • contamination at blood draw—collection/draw above intravenous infusion site may potentially contaminate the sample with IV fluids containing potassium, use of potassium containing antiseptic at the draw site

Processing and handling4,5

  • prolonged exposure of serum or plasma to cells—blood cells continue glycolysis in vitro in the collection tube. As the glucose is consumed, the Na+K+ATPase that maintains intracellular electrolyte concentration ceases to function
  • allowing serum samples to clot refrigerated—cold temperatures inhibit the function of Na+K+ATPase that maintains intracellular electrolyte concentration. Since cells contain a high concentration of potassium, it leaks out, causing in vitro elevation of potassium
  • re-centrifugation—causes potassium rich RBCs to release potassium during the re-spinning process
  • inappropriate centrifugation or improperly spun sample—RBCs can contaminate the separated serum and release potassium into the sample

 

Physiological factors that may cause in vitro potassium elevation

  • Hematologic disorders7-9
    • Thrombocytosis—platelets release potassium during the clotting process. With marked thrombocytosis, the potassium contribution from platelets can significantly increases serum potassium in vitro. A platelet count of >500*103 cells/µl has been shown to significantly alter measured serum potassium. Plasma potassium is not impacted
  • Leukocytosis—leukemic white blood cells are abnormally fragile and susceptible to lysis during sample handling. Markedly elevated leukocytes may cause an in vitro elevation in potassium from white blood cell lysis. Both serum and plasma samples may be impacted with plasma sample being more vulnerable. The risk of PHK increases as leukocyte count increases in which CLL and AML patients are particularly susceptible due to WBC fragility
  • Familial pseudo hyperkalemia6—This is a rare hereditary condition that results in "leaky" red cells in which RBCs show a temperature-dependent leakage of potassium when stored at room temperature

 

Employing appropriate draw techniques and handling is imperative in maintaining physiological potassium level representative of the patients' value at the time of draw.

Specimen Requirements

Specimen

Serum (preferred) or plasma

Volume

1 mL

Minimum Volume

0.7 mL (Note: This volume does not allow for repeat testing.)

Container

Red-top tube, gel-barrier tube or green-top (lithium heparin) tube. Do not use oxalate, EDTA or citrate plasma.

Collection Instructions

Separate serum or plasma from cells within 45 minutes of collection; avoid hemolysis.

Stability Requirements

TemperaturePeriod
Room temperature14 days
Refrigerated14 days
Frozen14 days
Freeze/thaw cyclesStable x3

Reference Range

See table.

AgeRange (mmol/L)
0 to 7 d3.7−5.2
8 to 30 d3.7−6.4
1 to 6 m3.8−6.0
7 m to 1 y3.8−5.3
>1 y3.5−5.2

Storage Instructions

Maintain specimen at room temperature or refrigerate.

Causes for Rejection

Hemolysis; improper labeling; unspun or improperly spun specimen

Footnotes

1. Clinical Laboratory Standards Institute (CLSI). Collection of Diagnostic Venous Blood Specimens, 1st ed. CLSI guideline PRE02. Clinical Laboratory Standards Institute; 2025.

2. Clinical Laboratory Standards Institute (CLSI). Handling, Transport, Processing, and Storage of Blood Specimens for Routine Laboratory Examinations, 1st ed. CLSI guideline PRE04. Clinical Laboratory Standards Institute; 2023.

3. Fulop M. Serum potassium in lactic acidosis and ketoacidosis. N Engl J Med. 1979 May 10;300(19):1087-1089 (review). PubMed 34793

4. Graber M, Subramani K, Corish D, Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis. 1988 Aug;12(2):116-120. PubMed 3400632

5. Hitz J, Trivin F. Potassium. In: Siest G, Galteau MM, eds. Drug Effects on Laboratory Test Results Analytical Interferences and Pharmacological Effects. Littleton, Mass: PSG Publishing Co Inc;1988: 362-374.

6. Meng QH, Wagar EA. Pseudohyperkalemia: A new twist on an old phenomenon. Crit Rev Clin Lab Sci. 2015;52(2):45-55. PubMed 25319088

7. Mir MA, Brabin B, Tang OT, Leyland MJ, Delamore IW. Hypokalemia in acute myeloid leukemia. Ann Intern Med. 1975 Jan;82(1):54-57. PubMed 16553

8. Thurlow V, Ozevlat H, Jones SA, Bailey IR. Establishing a practical blood platelet threshold to avoid reporting spurious potassium results due to thrombocytosis. Ann Clin Biochem. 2005 May;42(Pt 3):196-199. PubMed 15949154.

9. Ranjitkar P, Greene DN, Baird GS, Hoofnagle AN, Mathias PC. Establishing evidence-based thresholds and laboratory practices to reduce inappropriate treatment of pseudohyperkalemia. Clin Biochem. 2017 Aug;50(12):663-669. PubMed 28288853

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
001180 Potassium 2823-3 001180 Potassium mmol/L 2823-3
Order Code001180
Order Code NamePotassium
Order Loinc2823-3
Result Code001180
Result Code NamePotassium
UofMmmol/L
Result LOINC2823-3